Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics 18: Cell Cycle Mechanisms of Anticancer Drug Action

Ritonavir causes G1 arrest in non-small cell lung cancer (NSCLC), in part, by binding hsp90 and down-regulating Cdk4 and other Hsp90 client proteins

Anjaiah Srirangam, Mu Wang, Janice Blum, Lawrence Einhorn and David A. Potter
Anjaiah Srirangam
Indiana University School of Medicine, Indianapolis, IN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mu Wang
Indiana University School of Medicine, Indianapolis, IN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Janice Blum
Indiana University School of Medicine, Indianapolis, IN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence Einhorn
Indiana University School of Medicine, Indianapolis, IN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David A. Potter
Indiana University School of Medicine, Indianapolis, IN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2005
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 46, 2005

Abstract

2275

The HIV protease inhibitor, ritonavir, has been implicated as an inhibitor of cancer cell growth, but the mechanisms of its action are not established. Ritonavir inhibits the growth of the NCI-H522 human lung adenocarcinoma line, exhibiting an IC50 of 42±2 (mean±SEM) microM. Ritonavir causes a G0/G1 arrest, with an increase in the G0/G1 population from 38 to 73% and corresponding reduction of the G2/M population. Apoptosis is induced 3-fold by ritonavir compared to vehicle control at 24 h, from 3.8 to 11%, as measured by propidium iodide/Annexin-FITC staining, and increases with exposure time. In contrast, the proteasome inhibitor lactacystin fails to induce cell cycle arrest or apoptosis, suggesting that the effects of ritonavir are independent of proteasome inhibition. Surface EGFR is down-regulated 50% by ritonavir, as measured by flow cytometric analysis, as is total cellular EGFR. Other Hsp90 clients, including the glucocorticoid receptor, ErbB2, c-Raf1, ERK, Akt, mutant p53, and Cdk4 are similarly down-regulated by ritonavir. Phospho-ERK and phospho-Akt are also down-regulated by ritonavir, while Hsp90 is itself reduced by 50%. In contrast, p27 levels are not affected. These results suggest that ritonavir-induced G1 arrest of the H522 line is mediated, in part, by down-regulation of Hsp90 and resulting reduction of Cdk4. Similar down-regulation of Hsp90 and Cdk4 by ritonavir is observed for the A549 and H460 NSCLC lines. Surface plasmon resonance biosensor analysis revealed that ritonavir binds to human Hsp90, exhibiting a KD of 7.8 microM, in contrast to a KD of 0.65 microM for 17-allyamino-17-demethoxygeldanamycin (17-AAG). Because the KD of ritonavir for Hsp90 is well below the median Cmax of clinical serum ritonavir levels, 27 microM, clinical ritonavir dosing may potentially inhibit Hsp90 function. Ritonavir dramatically sensitizes the H522, A549 and H460 lines to the S-phase active chemotherapeutic agent, gemcitabine, exhibiting Chou-Talalay combination indices of 0.16±0.09, 0.57±0.33 and 0.19±0.05 (mean±SEM), respectively. Together, these results suggest that Hsp90 and Cdk4 are novel ritonavir targets in NSCLC and that ritonavir inhibition of Cdk4 may sensitize NSCLC lines to DNA replication-associated stress.

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 65 (9 Supplement)
May 2005
Volume 65, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Ritonavir causes G1 arrest in non-small cell lung cancer (NSCLC), in part, by binding hsp90 and down-regulating Cdk4 and other Hsp90 client proteins
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Ritonavir causes G1 arrest in non-small cell lung cancer (NSCLC), in part, by binding hsp90 and down-regulating Cdk4 and other Hsp90 client proteins
Anjaiah Srirangam, Mu Wang, Janice Blum, Lawrence Einhorn and David A. Potter
Cancer Res May 1 2005 (65) (9 Supplement) 534;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Ritonavir causes G1 arrest in non-small cell lung cancer (NSCLC), in part, by binding hsp90 and down-regulating Cdk4 and other Hsp90 client proteins
Anjaiah Srirangam, Mu Wang, Janice Blum, Lawrence Einhorn and David A. Potter
Cancer Res May 1 2005 (65) (9 Supplement) 534;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Cytotoxicity, cell cycle modification and apoptosis induction of oxaliplatin (LOHP) on human cancer cells
  • Thiazolidinediones inhibit cell growth of human ovarian cancer cells via PPAR-Γ & p53- independent pathway
  • Cell cycle effects of the EGFR TK inhibitor erlotinib in NSCLC cell lines
Show more Experimental and Molecular Therapeutics 18: Cell Cycle Mechanisms of Anticancer Drug Action
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement